New drug BHV-1300 tested for Graves' disease in early trial

NCT ID NCT06980649

Recruiting now Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 24 times

Summary

This early-stage study tests whether BHV-1300 is safe for people with Graves' disease, a condition where the immune system attacks the thyroid. Researchers will also look at how the drug affects certain markers of the disease. About 15 adults with confirmed Graves' disease will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site-001
RECRUITING

Kotara, 2289, Australia
Site-002
RECRUITING

Torquay, 3228, Australia
Site-003
RECRUITING

Melbourne, 3128, Australia
Site-004
RECRUITING

Fitzroy, 3065, Australia
Site-006
RECRUITING

St Leonards, 2065, Australia
Site-008
RECRUITING

Parkville, 3050, Australia
Site-010
RECRUITING

Oaklands Park, 5046, Australia
Site-100
RECRUITING

Miami, Florida, 33126, United States
Site-101
RECRUITING

Houston, Texas, 77095, United States
Site-103
RECRUITING

South Gate, California, 90280, United States
Site-104
RECRUITING

Columbus, Georgia, 31904, United States
Site-105
RECRUITING

Shavano Park, Texas, 78231, United States
Site-106
RECRUITING

Houston, Texas, 77054, United States

Conditions

Explore the condition pages connected to this study.

GRAVES DISEASE